Carcinoid Tumors

Continuing Education Activity

Carcinoid tumors are slow-growing tumors arising from neuroendocrine cells and capable of secreting a variety of peptides and neuroamines. The common primary sites are the gastrointestinal tract, accounting for 60 percent of the primary tumors, followed by the tracheobronchial tree, accounting for 25 percent of the primary tumors. Other primary sites include the ovaries and kidneys. Most carcinoid tumors occur in the small intestine. This activity reviews the cause, pathophysiology, and presentation of carcinoid tumors and highlights the role of the interprofessional team in its management.

Objectives:

• Assess the pathophysiology of carcinoid tumors.
• Evaluate the presentation of carcinoid tumors.
• Differentiate the treatment options for carcinoid cancer.
• Commnunicate the importance of optimizing care coordination among interprofessional team members to improve outcomes for patients with carcinoid tumors.

Introduction

Carcinoid tumors are slow-growing tumors arising from neuroendocrine cells and capable of secreting a variety of peptides and neuroamines. The common primary sites are the gastrointestinal (GI) tract (60%), followed by the tracheobronchial tree (25%), but other primaries may occur in the ovaries or kidneys. The most common location of carcinoids is the small intestine. The term carcinoid is usually used for well-differentiated and low to intermediate-grade neuroendocrine tumors, and the term neuroendocrine carcinoma is used for the less frequent, poorly differentiated, and high-grade neuroendocrine tumors. Gastrointestinal (GI) carcinoid tumors are the focus of this topic.[1][2]

Etiology

Carcinoid tumors are endodermal in origin and arise from enterochromaffin cells of the aerodigestive tract. GI carcinoids occur most frequently in the small bowel, followed by the rectum, appendix, and stomach. It has been proposed that paracrine agents and growth factors induce cell proliferation and form fertile ground for mutations in oncogenes and tumor suppressor genes. Carcinoids can also rarely be seen in patients with familial MEN1 syndrome.[3]

Epidemiology

The annual incidence is estimated to be 2.5 to 5 per 100,000 people per year, and prevalence is 35 per 100,000. The highest incidence is reported in patients around 50 to 70 years of age, with no gender predilection. With improved techniques for tumor detection, the incidence has increased.[4][5]

Pathophysiology

Carcinoid tumors are commonly classified based on their embryologic origins and the vascular supply of the GI tract into the foregut, midgut, and hindgut carcinoids. Functional carcinoids can secrete various vasoactive substances such as serotonin, histamine, tachykinins, and prostaglandins. Presentation with carcinoid syndrome usually indicates underlying hepatic metastatic disease, indicating a loss of the ability of the liver to inactivate these substances, but foregut carcinoids can release vasoactive amines directly into the systemic circulation. It can present with carcinoid syndrome without liver metastases. Embryonic hindgut carcinoids are rarely associated with a hormonal syndrome.[6]

Histopathology

The tumors are usually small, polyploid, solid, slow growing, often invading transmurally, and spread to the lymphatics and adjacent mesentery. The tumor cells are arranged in nests or trabeculae and characterized by lightly eosinophilic cytoplasm, variable nuclear grade, and round to oval finely granular nuclei. Immunostaining for general markers of neuroendocrine tumors such as chromogranin A and synaptophysin are frequently done for diagnostic confirmation. The WHO (2010) classified all neuroendocrine tumors, including carcinoids, into 3 grades based on the mitotic rate, or Ki-67 index: 

1. Low-grade, well-differentiated endocrine tumors with benign or uncertain behavior at the time of diagnosis with a mitotic rate of less than 2 and a Ki-67 index of less than 3% (10% to 30%)
2. Well-differentiated endocrine carcinomas with low-grade malignant behavior with a mitotic rate of 2 to 20 and Ki-67 index of 3% to 20% (50% to 80%)
3. High-grade, poorly differentiated endocrine carcinomas with high-grade malignant behavior, a mitotic rate of more than 20, and a Ki-67 index of more than 20% (1% to 3%).

History and Physical

The presentation of carcinoids depends on where they are located, hormonal activity, and tumor aggressiveness. Carcinoid syndrome from hypersecretion of vasoactive amines is most common with small intestinal carcinoids (up to 80%) but can also occur in foregut carcinoids in the lungs and ovaries. The most common clinical manifestations are episodic flushing (84%), watery diarrhea (70%), and heart disease (37%). Most of the episodic flushing occurs spontaneously, but physical and emotional stress, alcohol, and tyramine-containing foods like blue cheese, chocolate, and red wine can provoke it. Flushing associated with carcinoids is characteristically dry flushing, as opposed to common causes of flushing, such as panic attacks and menopause, which are associated with sweating. Leonine facies may result over time due to telangiectasia and hypertrophy of the skin. Diarrhea is secretory, and key in its history is its persistence with fasting. Other presentations could be bronchospasm, arthropathy, neuropathy, and edema. Bowel ischemia with abdominal pain and bleeding could result from mesenteric fibrosis associated with midgut carcinoids. The local mass effect of the tumor can cause bowel obstruction.

Chronic exposure to these amines can cause fibrous endocardial thickening of the right side of the heart with resultant tricuspid and pulmonary valve regurgitation leading to right heart failure. Left heart disease is uncommon due to the clearance of 5HT by monoamine oxidase present in the lung. Patients can also present with Pellagra as tryptophan is diverted from niacin synthesis to serotonin synthesis. These patients present with glossitis, angular stomatitis, a characteristic skin rash with rough, scaly skin, and confusion.

Evaluation

The diagnosis of these tumors is often delayed by 5 to 7 years as these patients are often asymptomatic or present with non-specific symptoms. Metastases occur in 30% of patients at the time of diagnosis and can be as high as 70% in midgut carcinoids. The diagnosis is mainly based on clinical suspicion and biochemical evaluation. Imaging is often used for localization and assessment of tumor spread.[7][8][9][10]

Biochemical Tests

It is recommended that all patients with carcinoid tumors have chromogranin A, pancreastatin, and 24-hour urine for 5-hydroxyindoleacetic acid (5-HIAA) checked. Chromogranin A, a non-specific neuroendocrine marker, can be useful in the screening and follow-up of both functioning and non-functioning carcinoids, like other neuroendocrine tumors. Levels should be obtained while fasting, and exercise should be avoided before testing. Chromogranin A levels correlate with tumor volume and may provide prognostic information. It can also be a useful tool for monitoring response to therapy. Small tumors may be associated with a normal level and thus missed. False-positive measurements can occur with severe hypertension, chronic gastritis, proton pump inhibitor use, and renal insufficiency. Results from different laboratories are not directly comparable, and it is important to send samples to the same laboratory when chromogranin A is used for serial monitoring. Pancreastatin, a post-translational processing product of chromogranin A, appears less susceptible to assay artifacts and use of proton pump inhibitors, may be a negative prognostic indicator, and can potentially be an alternate biomarker. 24-hour urine collection for 5-HIAA, a serotonin breakdown product, is useful for the diagnosis and follow-up of carcinoid tumors secreting serotonin, mainly midgut carcinoids. It is important to avoid certain foods (rich in serotonin and tryptophan) and medications that can result in false elevations of 5-HIAA for 3 days before and during collection. Serum serotonin is not useful due to variability from daily activities. Measuring single fasting plasma 5-HIAA levels is convenient but needs further study. Foregut carcinoids deficient in dopa-decarboxylase (converts 5-hydroxytryptophan to serotonin) lead to only modest elevations of 5-HIAA.

Imaging

CT with multiphase contrast study, MRI, somatostatin receptor scintigraphy with Octreoscan, and PET scan with DOTATOC are useful imaging modalities for localizing carcinoid tumors and assessing metastatic spread. CT is insensitive for small liver metastases, for which MRI with a hepatocyte-specific contrast agent is a better imaging modality. FDG-PET is not useful due to the low proliferative activity of carcinoid tumors. Upper and lower GI endoscopies are useful for direct visualization and biopsy of accessible lesions. CT enterography can also be used. Small bowel enteroscopy and pill-cam endoscopy are useful for small bowel tumors beyond the reach of standard endoscopy. Pill-cam can be retained at the tumor site with resultant small bowel obstruction, and therefore, routine use is not recommended. An echocardiogram is useful for detecting carcinoid valvular disease and should be done before surgery. Octreotide scan is useful for predicting treatment response to octreotide treatment.

Treatment / Management

Many patients with carcinoids have nonspecific symptoms, diagnosis is delayed, and metastatic disease is present at diagnosis. The goals of treatment are to resect the primary tumor and associated regional lymph nodes and to control carcinoid syndrome when present.[11][12][13] Surgical removal of the tumor is curative in localized disease, although finding the primary when small can be challenging. The goal of surgery in midgut carcinoids is complete curative en bloc resection of the primary tumor and extensive mesenteric lymph node dissection. Subserosal-injected methylene blue helps identify surgical margins for midgut carcinoids. Small intestinal carcinoids can cause a severe desmoplastic reaction and deeply infiltrative lymph nodes around major vessels, and thus, complete surgical resection is seldom achieved, but cytoreductive surgery (resection of 90% of the tumor) from an experienced surgical team results in improved symptomatic outcomes. Surgery should not be delayed until symptoms occur because this makes cytoreductive surgery more difficult. As most patients with midgut carcinoids require treatment with somatostatin analogs at some point, and these agents are associated with biliary stasis and cholelithiasis, cholecystectomy should be performed at the time of initial surgery. Small bowel obstruction is also an indication for surgery and is treated with resection of the involved segments and mesentery. All patients with metastatic carcinoids should be evaluated for a multimodality approach involving surgery, medical therapy, and radiotherapeutic techniques. Metastasectomy can also be curative in isolated metastasis and can also be used to decrease tumor bulk to provide relief in symptomatic patients. Liver-directed therapies for palliative control of advanced metastatic disease include chemoembolization and radioembolization.

 Somatostatin analogs (SA) are the mainstay of medical therapy for carcinoid syndrome due to the high expression of somatostatin receptors (SSTR) on these tumors. Octreotide and lanreotide bind to SSTR-2 and -5, reducing diarrhea and flushing in up to 80% of patients. Somatostatin analogs have been shown to control the growth of well-differentiated neuroendocrine tumors and to increase progression-free survival. Pancreatic malabsorption can occur with SAs and benefits from pancreatic enzyme supplementation. Tolerance to somatostatin analogs develops over time, requiring dose escalation. Refractory diarrhea may benefit from the use of loperamide. It has been recommended that all patients with functional or nonfunctional neuroendocrine tumors (including carcinoids) be considered for treatment with somatostatin analogs and have routine tumor surveillance. Interferon-alpha has a potential role in refractory symptoms of carcinoid syndrome despite somatostatin analog treatment. The role of mTOR inhibitors in the management of carcinoids needs further study. As carcinoids are slow-growing, traditional chemotherapy is ineffective. Peptide receptor radiotherapy utilizing somatostatin analog chelated to beta-emitting cytotoxic isotope 90-Yttrium or 177-Lutetium is an emerging therapeutic modality that utilizes the somatostatin receptor as a target. I 131 MIBG therapy is being used for metastatic neuroendocrine tumors with intense uptake and needs further studies.

Differential Diagnosis

The differential diagnosis for carcinoid tumors  include the following:

• Acute Urticaria
• Anaphylaxis
• Angioedema
• Celiac disease (sprue)
• Intestinal motility disorders
• Irritable bowel syndrome
• Ogilvie syndrome
• Tumor lysis syndrome

Pearls and Other Issues

Carcinoid crisis can occur due to excessive release of neuropeptides during stress and can present with hemodynamic instability, shock, arrhythmia, hyperthermia, bronchospasm, or flushing. It can also occur pre-op, intra-procedural, or post-op due to manipulation of the tumor. Patients with carcinoid syndrome and large bulky tumors or metastatic carcinoid may be at higher risk of carcinoid crisis and should be given perioperative continuous intravenous octreotide. Adrenergic-blocking agents like clonidine, chlorpromazine (kinin antagonist), corticosteroids (blocks kallikrein release), and aprotinin (a kallikrein inhibitor) have also been used in carcinoid crises. Before surgery, patients should undergo echocardiography for carcinoid valve disease and valve repair and be given prophylaxis with somatostatin analogs.

Enhancing Healthcare Team Outcomes

Carcinoid tumors are relatively common disorders, and their presentation can vary. These tumors can occur in several organs, and while they tend to grow locally, metastases are not uncommon. Because of their diverse presentation, they are best managed by an interprofessional team. The survival of patients with carcinoids depends on the location, grade, metabolic activity, and presence of metastases. Localized lesions have a 5-year survival of 85-90%, and outcomes of functioning lesions are better than non-functional tumors.[14][15][16]

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

Kristína MK, Pavol J, Andrea J, Zuzana Č. Histopathology of Neuroendocrine Neoplasms of the Gastrointestinal System. Klin Onkol. 2018 Spring;31(3):167-177. [PubMed: 30441969]

2.

Cives M, Strosberg J, Al Diffalha S, Coppola D. Analysis of the immune landscape of small bowel neuroendocrine tumors. Endocr Relat Cancer. 2019 Jan 01;26(1):119-130. [PMC free article: PMC7787268] [PubMed: 30400003]

3.

Cives M, Strosberg JR. Gastroenteropancreatic Neuroendocrine Tumors. CA Cancer J Clin. 2018 Nov;68(6):471-487. [PubMed: 30295930]

4.

Sackstein PE, O'Neil DS, Neugut AI, Chabot J, Fojo T. Epidemiologic trends in neuroendocrine tumors: An examination of incidence rates and survival of specific patient subgroups over the past 20 years. Semin Oncol. 2018 Aug;45(4):249-258. [PubMed: 30348533]

5.

Parikh PP, Perez EA, Neville HL, Hogan AR, Sola JE. Nationwide overview of survival and management of appendiceal tumors in children. J Pediatr Surg. 2018 Jun;53(6):1175-1180. [PubMed: 29656783]

6.

Rubin de Celis Ferrari AC, Glasberg J, Riechelmann RP. Carcinoid syndrome: update on the pathophysiology and treatment. Clinics (Sao Paulo). 2018 Aug 20;73(suppl 1):e490s. [PMC free article: PMC6096975] [PubMed: 30133565]

7.

Yoon JY, Sigel K, Martin J, Jordan R, Beasley MB, Smith C, Kaufman A, Wisnivesky J, Kim MK. Evaluation of the Prognostic Significance of TNM Staging Guidelines in Lung Carcinoid Tumors. J Thorac Oncol. 2019 Feb;14(2):184-192. [PubMed: 30414942]

8.

Gündoğar Ö, Kımıloğlu E, Komut N, Cin M, Bektaş S, Gönüllü D, İlgün AS, Erdoğan N. Evaluation of appendiceal mucinous neoplasms with a new classification system and literature review. Turk J Gastroenterol. 2018 Sep;29(5):533-542. [PMC free article: PMC6284620] [PubMed: 30260774]

9.

Laskaratos FM, Walker M, Wilkins D, Tuck A, Ramakrishnan S, Phillips E, Gertner J, Megapanou M, Papantoniou D, Shah R, Banks J, Vlachou E, Garcia-Hernandez J, Woodbridge L, Papadopoulou A, Grant L, Theocharidou E, Watkins J, Luong TV, Mandair D, Caplin M, Toumpanakis C. Evaluation of Clinical Prognostic Factors and Further Delineation of the Effect of Mesenteric Fibrosis on Survival in Advanced Midgut Neuroendocrine Tumours. Neuroendocrinology. 2018;107(3):292-304. [PubMed: 30153671]

10.

Feng M, Zou J, Zhang Y, Sun L. [Neuroendocrine carcinoma of cervix: a clinicopathologic study of 82 cases]. Zhonghua Bing Li Xue Za Zhi. 2018 May 08;47(5):328-333. [PubMed: 29783797]

11.

Galanopoulos M, Toumpanakis C. The Problem of Appendiceal Carcinoids. Endocrinol Metab Clin North Am. 2018 Sep;47(3):661-669. [PubMed: 30098722]

12.

Daskalakis K, Tsolakis AV. Upfront surgery of small intestinal neuroendocrine tumors. Time to reconsider? World J Gastroenterol. 2018 Aug 07;24(29):3201-3203. [PMC free article: PMC6079287] [PubMed: 30090001]

13.

Melosky B. Advanced typical and atypical carcinoid tumours of the lung: management recommendations. Curr Oncol. 2018 Jun;25(Suppl 1):S86-S93. [PMC free article: PMC6001761] [PubMed: 29910651]

14.

Ngamruengphong S, Kamal A, Akshintala V, Hajiyeva G, Hanada Y, Chen YI, Sanaei O, Fluxa D, Haito Chavez Y, Kumbhari V, Singh VK, Lennon AM, Canto MI, Khashab MA. Prevalence of metastasis and survival of 788 patients with T1 rectal carcinoid tumors. Gastrointest Endosc. 2019 Mar;89(3):602-606. [PubMed: 30447216]

15.

Kimbrough CW, Beal EW, Dillhoff ME, Schmidt CR, Pawlik TM, Lopez-Aguiar AG, Poultsides G, Makris E, Rocha FG, Crown A, Abbott DE, Fisher AV, Fields RC, Krasnick BA, Idrees K, Marincola-Smith P, Cho CS, Beems M, Maithel SK, Cloyd JM. Influence of carcinoid syndrome on the clinical characteristics and outcomes of patients with gastroenteropancreatic neuroendocrine tumors undergoing operative resection. Surgery. 2019 Mar;165(3):657-663. [PMC free article: PMC10182411] [PubMed: 30377003]

16.

Niu Q, Lu Y, Xu S, Shi Q, Guo B, Guo Z, Huang T, Wu Y, Yu J. Clinicopathological characteristics and survival outcomes of bladder neuroendocrine carcinomas: a population-based study. Cancer Manag Res. 2018;10:4479-4489. [PMC free article: PMC6190820] [PubMed: 30349380]

Disclosure: Shashank Cingam declares no relevant financial relationships with ineligible companies.

Disclosure: Sarang Kashyap declares no relevant financial relationships with ineligible companies.

Disclosure: Harsha Karanchi declares no relevant financial relationships with ineligible companies.